291 related articles for article (PubMed ID: 31015801)
1. Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients.
Chen L; Zhu D; Feng J; Zhou Y; Wang Q; Feng H; Zhang J; Jiang J
Cancer Cell Int; 2019; 19():101. PubMed ID: 31015801
[TBL] [Abstract][Full Text] [Related]
2. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
Zhou QH; Li KW; Chen X; He HX; Peng SM; Peng SR; Wang Q; Li ZA; Tao YR; Cai WL; Liu RY; Huang H
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959726
[TBL] [Abstract][Full Text] [Related]
3. The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma.
Zhu D; Liu Y; Chen J; Wang Q; Li Y; Zhu Y; Feng J; Jiang J
J Transl Med; 2022 Jul; 20(1):298. PubMed ID: 35794583
[TBL] [Abstract][Full Text] [Related]
4. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target.
Chen D; Chen W; Xu Y; Zhu M; Xiao Y; Shen Y; Zhu S; Cao C; Xu X
J Med Genet; 2019 Jan; 56(1):43-49. PubMed ID: 29967134
[TBL] [Abstract][Full Text] [Related]
5. Prognostic values of B7-H3, B7-H4, and HHLA2 expression in human pancreatic cancer tissues based on mIHC and spatial distribution analysis.
Zhu Y; Chen J; Liu Y; Zheng X; Feng J; Chen X; Jiang T; Li Y; Chen L
Pathol Res Pract; 2022 Jun; 234():153911. PubMed ID: 35489125
[TBL] [Abstract][Full Text] [Related]
6. Long Non-Coding RNA LUCAT1 Promotes Proliferation and Invasion in Clear Cell Renal Cell Carcinoma Through AKT/GSK-3β Signaling Pathway.
Zheng Z; Zhao F; Zhu D; Han J; Chen H; Cai Y; Chen Z; Xie W
Cell Physiol Biochem; 2018; 48(3):891-904. PubMed ID: 30032137
[TBL] [Abstract][Full Text] [Related]
7. Over-Expression and Prognostic Significance of HHLA2, a New Immune Checkpoint Molecule, in Human Clear Cell Renal Cell Carcinoma.
Zhang Z; Liu J; Zhang C; Li F; Li L; Wang D; Chand D; Guan F; Zang X; Zhang Y
Front Cell Dev Biol; 2020; 8():280. PubMed ID: 32509772
[TBL] [Abstract][Full Text] [Related]
8. H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro.
Luo M; Xiong Y; Lin Y; Liang R; Li Y; Ge L
Med Sci Monit; 2021 May; 27():e930215. PubMed ID: 33990536
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma.
Zhu Z; Dong W
Onco Targets Ther; 2018; 11():1563-1570. PubMed ID: 29593422
[TBL] [Abstract][Full Text] [Related]
10. B7 score and T cell infiltration stratify immune status in prostate cancer.
Zhou Q; Li K; Lai Y; Yao K; Wang Q; Zhan X; Peng S; Cai W; Yao W; Zang X; Xu K; Huang J; Huang H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34417325
[TBL] [Abstract][Full Text] [Related]
11. High-level S100A6 promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma.
Lyu X; Li H; Ma X; Li X; Gao Y; Ni D; Shen D; Gu L; Wang B; Zhang Y; Zhang X
Cell Biochem Biophys; 2015 Jan; 71(1):279-90. PubMed ID: 25120023
[TBL] [Abstract][Full Text] [Related]
12. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
[TBL] [Abstract][Full Text] [Related]
13. HHLA2 is more significantly associated with poor prognosis in TSCC than PD-L1.
Li Y; Yang Q; Yang X; Ge J; Xu T; Liu H
J Oral Pathol Med; 2024 Feb; 53(2):159-168. PubMed ID: 38321252
[TBL] [Abstract][Full Text] [Related]
14. A Novel Biomarker, FKBP10, for Poor Prognosis Prediction in Patients with Clear Cell Renal Cell Carcinoma.
Xiao Y; Li S; Zhang M; Liu X; Ju G; Hou J
Evid Based Complement Alternat Med; 2022; 2022():5490644. PubMed ID: 35722147
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of Potential Immune Checkpoint Member HHLA2 in Human Tumors: A Comprehensive Analysis.
Wang B; Ran Z; Liu M; Ou Y
Front Immunol; 2019; 10():1573. PubMed ID: 31379814
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-induced overexpression of stanniocalcin-1 is associated with the metastasis of early stage clear cell renal cell carcinoma.
Ma X; Gu L; Li H; Gao Y; Li X; Shen D; Gong H; Li S; Niu S; Zhang Y; Fan Y; Huang Q; Lyu X; Zhang X
J Transl Med; 2015 Feb; 13():56. PubMed ID: 25740019
[TBL] [Abstract][Full Text] [Related]
17. HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
Huang FX; Wu JW; Cheng XQ; Wang JH; Wen XZ; Li JJ; Zhang Q; Jiang H; Ding QY; Zhu XF; Zhang XS; Ding Y; Li DD
Front Immunol; 2022; 13():902167. PubMed ID: 36003385
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
19. Novel immune scoring dynamic nomograms based on B7-H3, B7-H4, and HHLA2: Potential prediction in survival and immunotherapeutic efficacy for gallbladder cancer.
Lv C; Han S; Wu B; Liang Z; Li Y; Zhang Y; Lang Q; Zhong C; Fu L; Yu Y; Xu F; Tian Y
Front Immunol; 2022; 13():984172. PubMed ID: 36159808
[TBL] [Abstract][Full Text] [Related]
20. DDX39B Predicts Poor Survival and Associated with Clinical Benefit of Anti-PD-L1 Therapy in ccRCC.
Wei J; Lu J; Cao Y; Yao G; Huang Y; Zhao H; Pan Y; Feng Z; Chen Z; Chen W; Luo J; Cao J
Curr Cancer Drug Targets; 2021; 21(10):849-859. PubMed ID: 34382524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
